PF-AtlasClinical Trials › NCT02885961

The Coagulation Cascade in Idiopathic Pulmonary Fibrosis

Dabigatran · Not specified

Registry ID
NCT02885961
Phase
Not specified
Status
Unknown
Drug / intervention
Dabigatran
Sponsor
University College, London
Start
2016-08
Enrollment
12

About this trial

The pathogenesis of idiopathic pulmonary fibrosis (IPF) is incompletely understood but recurrent epithelial injury occurs which evokes the coagulation cascade. Thrombin is produced as a result and is over expressed in IPF patients, so may be important in propagating disease activity. We aim to recruit patients with IPF and then complete FDG (18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET (positron emission tomography) scans pre and post manipulation of the coagulation cascade to assess the role of this biological pathway in disease activity. Previous studies from our institution have demonstrated increased FDG avidity in the lungs of patients with IPF (assessed using FDG PET scans) but to date the cells and pathways responsible for this signal have not been identified and thus need further exploration.

View NCT02885961 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT02885961 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.